AX-2024-004424 · Semax · GSP lot GSP-2404-P2784

Section 1

Results

Measured against the index acceptance specification for the neuroactive and cognitive peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.93	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.07	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — des-Met (−131 Da)	0.05	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	87.04	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	86.98	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	11.60	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	10.090	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	100.9	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	8.07	%	≤ 12.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.70	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.19	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.97	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	7.13	min	7.06 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.97	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	72,150	—	≥ 20,000	PASS
Resolution to nearest impurity	vs diketopiperazine (−18 Da)	1.47	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 72,150, and skew follows the reported asymmetry factor of 0.97. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.05 % impurity against a 99.93 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Semax — main peak	7.13	4,856,908	99.93	—
2	des-Met (−131 Da)	7.33	2,430	0.05	-131.040
3	diketopiperazine (−18 Da)	7.29	972	0.02	-18.011
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	8.07
Counter-ion (acetate)	ion chromatography	4.70
Residual solvent + inorganic residue	estimated	0.19
Total peptide content	by difference	87.04
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.87	99.93	divergence -0.06 pp vs batch median
Total impurities (% area)	0.13	0.07
Largest single impurity (% area)	0.08	0.05
Water (%)	not stated	8.07
Counter-ion (%)	not stated	4.70
Peptide content (%w/w)	not stated	87.04
Endotoxin (EU/mg)	0.50	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Laboratory-retained
Evidentiary weight: Provenance documented, selection uncontrolled.
Chain of custody: Laboratory retained sample (−20 °C, 4 d since original receipt) → re-assay.
Assay date: 07 Jul 2024
Submitted to the index: 27 Jul 2024
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

buyer_sourced27 Jul 2024

Provenance and purity together are what make a figure like this usable. An independently purchased vial at 99.93 % is worth several supplier-selected ones.

method_absent27 Jul 2024

A resolution figure without a stated column and gradient is uninterpretable. Both are on this record, which is why the figure is worth printing at all.

Section 7

Related records

Same batch — lot GSP-2404-P2784 n=13

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2024-004416	GSP-2404-P2784	Janoshik	2024-Q3	99.93	8.00	—	Buyer-sourced	0	PASS
AX-2024-004417	GSP-2404-P2784	PeptideMeter	2024-Q3	99.50	8.18	—	Buyer-sourced	0	PASS
AX-2024-004418	GSP-2404-P2784	Janoshik	2024-Q3	99.69	7.60	—	Buyer-sourced	0	PASS
AX-2024-004419	GSP-2404-P2784	Janoshik	2024-Q3	99.93	8.17	—	Supplier-supplied	0	PASS
AX-2024-004420	GSP-2404-P2784	Medutest	2024-Q3	99.93	7.98	88.6	Buyer-sourced	1	MARGINAL
AX-2024-004421	GSP-2404-P2784	PeptideMeter	2024-Q3	99.93	9.04	97.0	Laboratory-retained	0	PASS
AX-2024-004422	GSP-2404-P2784	Janoshik	2024-Q3	99.88	8.98	—	Buyer-sourced	0	PASS
AX-2024-004423	GSP-2404-P2784	Medutest	2024-Q3	99.85	8.20	104.6	Buyer-sourced	0	PASS
AX-2024-004425	GSP-2404-P2784	Medutest	2024-Q3	99.93	7.73	102.8	Buyer-sourced	0	PASS
AX-2024-004426	GSP-2404-P2784	PeptideMeter	2024-Q3	99.77	8.78	93.3	Buyer-sourced	0	PASS
AX-2024-004427	GSP-2404-P2784	Janoshik	2024-Q3	99.93	8.53	—	Buyer-sourced	0	PASS
AX-2024-004428	GSP-2404-P2784	Medutest	2024-Q3	99.93	8.02	101.9	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Semax records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042519	Homopeptide	HOMO-2605-S5227	Medutest	2026-Q3	99.75	5.55	—	Buyer-sourced	PASS
AX-2026-042517	Homopeptide	HOMO-2605-S5227	Janoshik	2026-Q3	99.92	5.88	—	Buyer-sourced	PASS
AX-2026-042518	Homopeptide	HOMO-2605-S5227	Janoshik	2026-Q3	99.76	5.61	—	Buyer-sourced	PASS
AX-2026-042524	Homopeptide	HOMO-2605-S5227	Janoshik	2026-Q3	99.93	5.75	100.9	Supplier-supplied	PASS
AX-2026-042516	Homopeptide	HOMO-2605-S5227	Janoshik	2026-Q3	99.93	5.87	95.1	Buyer-sourced	PASS
AX-2026-042522	Homopeptide	HOMO-2605-S5227	Nordanalyt	2026-Q3	99.93	5.49	—	Buyer-sourced	PASS
AX-2026-042520	Homopeptide	HOMO-2605-S5227	Medutest	2026-Q3	99.93	6.12	—	Buyer-sourced	PASS
AX-2026-042514	Homopeptide	HOMO-2605-S5227	Janoshik	2026-Q3	99.59	5.48	97.0	Buyer-sourced	PASS

Other recent GSP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041831	Survodutide	GSP-2603-E3156	Kestrel	2026-Q3	99.91	5.50	93.2	Buyer-sourced	0	PASS
AX-2026-041836	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.65	5.34	90.3	Buyer-sourced	0	PASS
AX-2026-041837	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.33	5.37	—	Buyer-sourced	0	PASS
AX-2026-041833	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.08	4.91	99.3	Buyer-sourced	0	PASS
AX-2026-041832	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	98.01	5.14	99.5	Buyer-sourced	0	PASS
AX-2026-041835	Survodutide	GSP-2603-E3156	Nordanalyt	2026-Q3	98.34	5.74	89.0	Buyer-sourced	1	MARGINAL
AX-2026-041834	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	97.92	5.95	—	Buyer-sourced	0	PASS
AX-2026-041838	Survodutide	GSP-2603-E3156	PeptideMeter	2026-Q3	98.30	5.01	102.4	Buyer-sourced	0	PASS